AAVXF:OTCMKTS
Abivax SA
၁၃၉.၀၀ US$
၀.၀၀%
(၀.၀၀) 1D
ဇူ ၉, GMT-၄ ၀၉:၃၀:၀၁ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AAVXF...
Mkt. cap
၆၇၄.၄၂ ဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁၃၉.၀၀ US$
52-wk low
၇၁.၂၆ US$
Beta
၃.၀၉
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
Mkt. cap
၆၇၄.၄၂ ဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁၃၉.၀၀ US$
52-wk low
၇၁.၂၆ US$
Beta
၃.၀၉
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
News stories
From web sources and news partners
https://www.dars.gov.et/
·
ပြီးခဲ့သည့် ၁ ပတ်
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending Continues - Healthcare Earnings Report
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees၉၈
Founded၂၀၁၃ ဒီ ၄
Headquarters-
Sector-
Websiteabivax.com